North America Patient Derived Xenografts/PDX Models Market (2025-2030)
The North America Patient Derived Xenografts/PDX Models Market was valued at $162.3 Million in 2025 and projected to reach to $249.9 Million by 2030, representing a compound annual growth rate of 9.0%. North America's PDX Models market is positioned for sustained growth through 2030, supported by the region's unmatched pharmaceutical innovation capacity and regulatory environment.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
North America Patient Derived Xenografts/PDX Models Market Trends and Insights
- In North America, the adoption of PDX models is driven by robust pharmaceutical R&D infrastructure, increasing oncology drug development pipelines, and strong regulatory support for personalized medicine approaches.
- North America's leadership in precision oncology and biotech innovation positions the region as a critical hub for PDX model utilization across contract research organizations and academic institutions. The North America market benefits from substantial investment in cancer research and a mature ecosystem of CROs specializing in xenograft services.
- North America's pharmaceutical companies increasingly leverage PDX models to improve drug efficacy predictions and reduce late-stage clinical trial failures.
- Between 2025 and 2030, North America is expected to maintain its competitive advantage through technological advancements in tumor engraftment techniques and expanded applications beyond oncology into immunotherapy and combination therapy studies..
Key Market Statistics
- CAGR (2025-2030) 9.0% CAGR
- Market Size, 2025 ~USD 162.3 Million
- Forecast, 2030 ~USD 249.9 Million
- Geography North America
North America Patient Derived Xenografts/PDX Models Market Overview
Leading US Market Dominance :
The US commands $217 million of North America's PDX market in 2025, representing 84% of regional value. This dominance reflects the world's largest pharmaceutical R&D ecosystem, extensive cancer research infrastructure, and highest adoption rates of precision medicine technologies among North American institutions.
Strong 9% Regional CAGR :
North America's PDX market grows at 9% CAGR through 2030, reaching $249.9 million. This steady expansion outpaces many mature markets, driven by increasing oncology drug pipelines, FDA support for personalized therapeutics, and rising investment in translational cancer research across the region.
Robust Pharmaceutical R&D Infrastructure :
North America hosts the world's most advanced pharmaceutical development ecosystem with leading CROs, academic medical centers, and biotech hubs. This infrastructure accelerates PDX model adoption for preclinical oncology studies, enabling faster drug candidate validation and reducing development timelines.
Regulatory Support for Personalized Medicine :
FDA and Health Canada actively promote companion diagnostics and personalized treatment approaches, creating favorable conditions for PDX model integration into drug development workflows. Regulatory pathways increasingly recognize PDX-derived data for supporting IND and NDA submissions in oncology programs.
North America Patient Derived Xenografts/PDX Models Market Dynamics
- The US market's $217 million valuation reflects deep institutional adoption among major pharma, biotech firms, and academic research centers pursuing precision oncology strategies.
- Canada contributes $38.6 million, benefiting from collaborative research initiatives and government funding for cancer research infrastructure. The 9% CAGR trajectory reflects increasing demand for patient-derived models that better predict clinical outcomes compared to traditional xenografts.
- North American institutions are expanding PDX capabilities to support immuno-oncology programs, combination therapy development, and biomarker-driven patient stratification.
- Continued investment in genomic profiling, tumor banking, and CRO service expansion will drive market expansion through 2030..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- North America's PDX Models market will grow from $162.3M (2025) to $249.9M (2030), representing a 9.0% CAGR.
- North America leads global PDX adoption due to advanced pharmaceutical infrastructure and strong regulatory frameworks supporting personalized medicine.
- North America's CRO ecosystem and academic partnerships drive innovation in xenograft technology and expand applications beyond traditional oncology.
- North America's market growth is fueled by increasing demand for predictive preclinical models to reduce drug development costs and clinical trial failures.
Patient Derived Xenografts/PDX Models Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ORTHOTOPIC IMPLANTATION (Implantation Method) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.5% from 2025 to 2030 |
| Largest Segment | PDX MODELS (Model Type & Service) |
| Market Size Base Year (Billions) | ~USD 0.37 (2025) |
| Revenue Forecast (Billions) | ~USD 0.66 (2030) |
| Segments Covered | Model Type & Service, Type, Implantation Method |
North America Patient Derived Xenografts/PDX Models Market Report Segmentation
3 segment dimensions are covered across the global market.
By Model Type & Service
- Pdx Models
- Pdx Services
By Type
- Cryopreservation Services
- Model Characterization Services
- Model Creation & Expansion Services
- Mouse Model
- Other Pdx Services
- Rat Model
By Implantation Method
- Orthotopic Implantation
- Other Implantation Methods
- Subcutaneous Implantation
Target Audience
- Pharmaceutical Companies : Major pharma and biotech firms in North America require PDX market intelligence to optimize oncology drug development strategies, evaluate CRO partnerships, and allocate R&D budgets. Regional market data supports decision-making on in-house PDX capabilities versus outsourced services.
- Contract Research Organizations (CROs) : North American CROs need detailed market sizing and growth forecasts to justify PDX service expansion, facility investments, and talent recruitment. Regional data enables competitive positioning and identification of underserved market segments within the US and Canada.
- Academic Medical Centers : Research institutions across North America use market data to secure funding for PDX core facilities, justify infrastructure investments, and benchmark their capabilities against peer institutions. Regional insights support grant applications and collaborative partnership development.
- Technology and Service Vendors : Companies providing genomic profiling, tumor banking, data analytics, and PDX-related technologies need North America-specific market data to target customers, forecast revenue potential, and develop region-appropriate product strategies for the US and Canadian markets.
- Investment and Private Equity Firms : Investors evaluating acquisition targets, portfolio companies, and growth opportunities in the PDX space require detailed North American market analysis. Regional data supports valuation models, growth projections, and strategic fit assessments for oncology research service providers.
Key Companies in the North America Patient Derived Xenografts/PDX Models Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CHARLES RIVER LABORATORIES | United States | Public Company | Research Models and Services,Discovery and Safety Assessment,Manufacturing Solutions, |
| THE JACKSON LABORATORY | United States | Foundation/Charitable Institution | Mouse breeding & colony management,Phenotyping, efficacy testing & study-ready induced models,Genetic research services & bioinformatics, |
| INOTIV | United States | Public Company | Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software, |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, CMP, display, 3D printing),Plastics (ABS, AES, AS, ASA resins),Life Sciences (diagnostics, reagents, bioprocess, drug discovery support), |
| GENOWAY | France | Public Company | Custom mouse models (KO/KI, humanized, immune checkpoint),Custom rat models (KO/KI, immunodeficient, reconstituted),Custom cell lines (KO/KI, reporter, inducible), |
| BIOCYTOGEN PHARMACEUTICALS CO., LTD. | China | Public Company | Gene-Editing Services,Pharmacological Efficacy and Toxicology Services,Model Animals, |
| CHAMPIONS ONCOLOGY, INC. | United States | Public Company | Tumorgraft-based translational oncology services,Personalized cancer care / patient-specific Tumorgraft programs,Lumin Bioinformatics and data-driven software, |
| PHARMARON | China | Public Company | Laboratory Services,Chemical and Formulation Process Development and Manufacturing Services (Small Molecule CDMO),Clinical Research Services, |
| SYNGENE INTERNATIONAL LIMITED | India | Public Company | Discovery services (chemistry and biology),Development services (preclinical, CMC, clinical development),Manufacturing (API and drug product, including biologics), |
| LABCORP | United States | Public Company | Routine and preventive diagnostics (chemistry, hematology, urinalysis, wellness),Specialty and esoteric testing (genetic, oncology, infectious disease, women’s health),Biopharma laboratory services and clinical trial testing, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environmental Testing,Biopharma Testing and Services, |
CHARLES RIVER LABORATORIES
Charles River Laboratories is a public company founded in 1947 and headquartered in the United States. With 19,000 employees, it operates as a major provider of preclinical and clinical laboratory services.
THE JACKSON LABORATORY
The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States. The organization employs 2,100 staff members and focuses on genetic research and related scientific services.
INOTIV
INOTIV is a public company founded in 1974 and based in the United States. The company operates with 1,996 employees and provides research and development services.
JSR CORPORATION
JSR Corporation is a private company founded in 1948 and headquartered in Japan. With 7,997 employees, the company operates across multiple business segments.
GENOWAY
GENOWAY is a public company founded in 1999 and based in France. The organization employs 157 staff members and operates in the biotechnology sector.
BIOCYTOGEN PHARMACEUTICALS CO., LTD.
BIOCYTOGEN PHARMACEUTICALS CO., LTD. is a public company founded in 2008 and based in China. The company employs 1,443 staff members and operates in the pharmaceutical and biotechnology sectors.
CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc. is a public company founded in 1985 and based in the United States. The company employs 214 staff members and operates in the oncology research and services sector.
PHARMARON
PHARMARON is a public company founded in 2004 and based in China. With 25,088 employees, the company provides drug discovery and development services.
SYNGENE INTERNATIONAL LIMITED
Syngene International Limited is a public company founded in 1993 and headquartered in India. The organization employs 6,692 staff members and provides integrated drug discovery and development services.
LABCORP
LabCorp is a public company founded in 1995 and based in the United States. With 66,385 employees, it operates as a major provider of clinical laboratory and diagnostic services.
EUROFINS SCIENTIFIC
Eurofins Scientific is a public company founded in 1987 and headquartered in Luxembourg. The organization employs 65,694 staff members and provides laboratory testing and analytical services across multiple industries.
Countries within North America - compare and drill down
| Country | 2025 size (native) |
|---|---|
| US | USD 217 Million |
| Canada | USD 38.6 Million |
Country market size visualization
Reasons to Buy this Report
- US Market Dominance Insights : Gain detailed understanding of the $217 million US PDX market, including adoption rates among top pharma companies, biotech firms, and academic institutions. Identify key growth drivers specific to American oncology drug development pipelines and precision medicine initiatives.
- Regional Growth Trajectory Analysis : Access comprehensive forecasts showing North America's 9% CAGR through 2030, with granular projections for US and Canadian markets. Understand market dynamics that differentiate North American growth from global trends and competitive positioning.
- Regulatory Landscape Assessment : Evaluate FDA and Health Canada's evolving support for PDX-derived data in drug development submissions. Understand how regulatory pathways are accelerating PDX adoption and creating market opportunities for service providers and technology vendors.
- Competitive Landscape Mapping : Identify leading CROs, biotech companies, and academic centers driving PDX adoption across North America. Benchmark market share, service offerings, and strategic partnerships to inform competitive strategy and partnership opportunities in the region.
- Investment and Expansion Strategy : Leverage North America-specific market data to guide capital allocation, facility expansion, and service development decisions. Identify high-growth segments within oncology, emerging therapeutic areas, and geographic hotspots for PDX model demand across the region.
Frequently asked questions
What is the current market size of PDX Models in North America?
North America's PDX Models market was valued at $162.3 million in 2025 and is projected to reach $249.9 million by 2030.
What is the expected growth rate for North America's PDX market?
North America's PDX Models market is expected to grow at a compound annual growth rate (CAGR) of 9.0% from 2025 to 2030.
Why is North America a leading market for PDX models?
North America dominates the PDX market due to its advanced pharmaceutical R&D infrastructure, strong regulatory support for precision medicine, mature CRO ecosystem, and substantial cancer research investments.
What are the primary applications of PDX models in North America?
In North America, PDX models are primarily used for oncology drug development, immunotherapy research, combination therapy studies, and predictive efficacy testing to reduce clinical trial failures.
Which sectors drive demand for PDX models in North America?
North America's PDX market is driven by pharmaceutical companies, contract research organizations (CROs), academic medical centers, and biotechnology firms focused on precision oncology and personalized medicine development.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global PDX model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the PDX model market. The secondary sources used for this study include World Health Organization (WHO), American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory of Cell Therapy, International Journal of Non-Communicable Diseases, European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data were collected and analyzed to determine the overall size of the global PDX model market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the PDX model market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Patient-derived xenografts (PDXs) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse. These models have been used to grow cancer tissues after they were removed from a patient. The PDX model is an important tool for cancer research. It is used to study the biology of cancer, test the efficacy of new therapies, and predict the response to therapy in individual patients.
The study offers an in-depth analysis of the PDX model market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key PDX model product providers.
Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Academic & research institutes
- Preclinical and translational research centers
- Life science companies
- Regulatory bodies
- Contract development and manufacturing organizations (CDMOs)
- Cancer research consortia & foundations
- Venture capitalists & strategic investors
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the PDX model market based on implantation method, type, tumor type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall PDX model market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the PDX model market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the PDX model market
- To benchmark players within the PDX model market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Get the Full Patient Derived Xenografts/PDX Models Market Report
Full forecast, segment splits, and company analysis for all Patient Derived Xenografts/PDX Models Market.
- Canada Patient Derived Xenografts/PDX Models Market
- US Patient Derived Xenografts/PDX Models Market
- Germany Patient Derived Xenografts/PDX Models Market
- UK Patient Derived Xenografts/PDX Models Market
- France Patient Derived Xenografts/PDX Models Market
- Italy Patient Derived Xenografts/PDX Models Market
- Spain Patient Derived Xenografts/PDX Models Market
- China Patient Derived Xenografts/PDX Models Market
- Japan Patient Derived Xenografts/PDX Models Market
- India Patient Derived Xenografts/PDX Models Market
- Australia Patient Derived Xenografts/PDX Models Market
- South Korea Patient Derived Xenografts/PDX Models Market
- Brazil Patient Derived Xenografts/PDX Models Market
- Mexico Patient Derived Xenografts/PDX Models Market
- UAE Patient Derived Xenografts/PDX Models Market
- Rest Of Europe Patient Derived Xenografts/PDX Models Market
- Rest Of Asia Pacific Patient Derived Xenografts/PDX Models Market
- Rest Of Latin America Patient Derived Xenografts/PDX Models Market
- Kingdom Of Saudi Arabia Patient Derived Xenografts/PDX Models Market
- Rest Of GCC Countries Patient Derived Xenografts/PDX Models Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report